GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Land And Improvements

GALDY (Galderma Group AG) Land And Improvements : $363 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Land And Improvements?

Galderma Group AG's land and improvements for the quarter that ended in Jun. 2024 was $363 Mil.

Galderma Group AG's quarterly land and improvements stayed the same from . 20 ($0 Mil) to Jun. 2023 ($0 Mil) but then increased from Jun. 2023 ($0 Mil) to Jun. 2024 ($363 Mil).

Galderma Group AG Land And Improvements Historical Data

The historical data trend for Galderma Group AG's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Land And Improvements Chart

Galderma Group AG Annual Data
Trend
Land And Improvements

Galderma Group AG Semi-Annual Data
Jun23 Jun24
Land And Improvements - 363.00

Galderma Group AG Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Land And Improvements
Comparable Companies
Traded in Other Exchanges
GDERF:USA GALDz:UK GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.